Evaluation of residual tumor locations in advanced ovarian cancer patients after incomplete primary cytoreduction

Background: Nowadays complete primary cytoreduction can be achieved in a large number of patients suffering from advanced ovarian cancer. However, there is a group of patients in whom complete tumor resection remains impossible. The authors analyzed the intraoperative limiting factors in patients with residual tumor after primary surgery treated in the present institution. Materials and Methods: Patients with advanced epithelial ovarian cancer (FIGO Stage IIIB-IV), who underwent primary incomplete surgery in the present institution between 2006 and 2008 were included in this study. Patients’ records were evaluated regarding to intraoperative findings and final surgical results. Results: The authors identified 39 eligible patients in their registry. Twenty-six (66.7%) patients underwent surgery with residual tumor < 1 cm and 13 (33.3%) ≥ 1 cm. The most frequent location of residual tumor limiting complete surgery was disseminated bowel carcinomatosis in 34 (87.2%) patients. Moreover significant differences in tumor residuals locations and operative time between patients with residuals < 1 cm and ≥ 1 cm were reported (p < 0.05). Conclusions: The most frequent reason for incomplete primary cytoreduction remains disseminated carcinomatosis. However, in patients with residuals under one cm, its frequency is significantly higher. The complication rate is comparable in patients independently of residual tumor < 1 cm and ≥ 1 cm. Therefore the cytoreductive efforts should be made even in primarily not completely operated patients in order to achieve residuals under one cm.

Primary ovarian cancer; Advanced ovarian cancer; Incomplete cytoreduction.

[1] Sant M., Allemani C., Santaquilani M., Knijn A., Marchesi F., Capocaccia R.: “EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary”. Eur. J. Cancer, 2009, 45, 931.

[2] Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun MJ.: “Cancer statistics, 2009”. C.A. Cancer J. Clin., 2009, 59, 225.

[3] Heintz A.P., Odicino F., Maisonneuve P., Quinn M.A., Benedet J.L., Creasman W.T., et al.: “Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer”. Int. J. Gynaecol. Obstet., 2006, 95, S161.

[4] Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., Montz F.J.: “Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis”. J. Clin. Oncol., 2002, 20, 1248.

[5] du Bois A., Reuss A., Pujade-Lauraine E., Harter P., Ray-Coquard I., Pfisterer J.: “Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)”. Cancer, 2009, 115, 1234.

[6] Harter P., Muallem M.Z., Buhrmann C., Lorenz D., Kaub C., Hils R., et al.: “Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer”. Gynecol. Oncol., 2011, 121, 615.

[7] du Bois A., Rochon J., Pfisterer J., Hoskins W.J.: Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol. Oncol., 2009, 112, 422.

[8] Bristow R.E., Zahurak ML, Diaz-Montes T.P., Giuntol R.L., Armstrong D.K.: “Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes:. Gynecol. Oncol., 2009, 115, 334.

[9] Kommoss S., Rochon”J., Harter P., Heitz F., Grabowski J.P., Ewald- Riegler N., et al.: “Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer”. Ann. Surg. Oncol., 2010, 17, 279.

[10] du Bois A., Rochon J., Lamparter C., Pfisterer J.: “Die Qualität der Therapie des Ovarialkarzinoms in Deutschland - Dritte Stufe der Qualitätssicherungserhebung QS-OVAR der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Kommission OVAR. Frauenarzt, 2009, 9, 742.

[11] Rochon J., du Bois A.: “Clinical research in epithelial ovarian cancer and patients' outcome”. Ann. Oncol., 2011, 22, vii16.

[12] Vergote I., Tropé C.G., Amant F., Kristensen G.B., Ehlen T., Johnson N., et al.: “Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer”. N. Engl. J. Med., 2010, 363, 943.

[13] Eisenkop S.M., Friedman R.L., Wang HJ.: “Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study”. Gynecol. Oncol., 1998, 69, 103.

[14] Aletti G.D., Dowdy S.C., Gostout B.S., Jones M.B., Stanhope R.C., Wilson T.O., et al.: “Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience”. J. Am. Coll. Surg., 2009, 208, 614.

[15] Al Rawathi T., Lopes A.D., Bristow R.E., Bryant A., Elattar A., Chattopadhyay S., Galaal K.: “Surgical cytoreduction for recurrent epithelial ovarian cancer”. Cochrane Database Syst. Rev.. 2013, 2, CD008765. doi: 10.1002/14651858.CD008765.pub3. Review.

[16] Grabowski J.P., Harter P., Buhrmann C., Lorenz D., Hils R., Kommoss S., et al.: “Re-operation outcome in patients referred to a gynecologic oncology center with presumed ovarian cancer FIGO I-IIIA after sub-standard initial surgery”. Surg. Oncol. 2012, 21, 31.

[17] Grabowski J.P., Harter P., Hils R., Lorenz D., Kaub C., Barinoff J. et al.: “Outcome of immediate re-operation or interval debilking after chemotherapy at a gynecologic oncology center after initially incomplete cytoreduction of advanced ovarian cancer” Gynecol. Oncol., 2012, 126, 54.

[18] Aletti G.D., Gostout B.S., Podratz K.C., Cliby W.A.: “Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon”. Gynecol. Oncol. 2006;100:33-7

[19] Fotopoulou C., Richter R., Braicu E.I., Schmidt S.C., Lichtenegger W., Sehouli J.: “Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients”. Eur. J. Surg. Oncol., 2010, 36, 1202.

[20] Scholz H.S., Tasdemir H., Hunlich T., Turnwald W., Both A., Egger H.: “Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: results and 5-year follow-up”. Gynecol. Oncol., 2007, 106, 591.

[21] Braicu I.E., Sehouli J., Richter R., Pietzner K., Lichtenegger W., Fotopoulou C.: “Primary versus secondary cytoreduction for epithelial ovarian cancer: A paired analysis of tumor pattern and surgical outcome”. Eur. J. Cancer, 2012, 48, 687.

[22] Sehouli J., Savvatis K., Braicu E.I., Schmidt S.C., Neuhaus P., Lichtenegger W., et al.: “Primary versus interval debulking surgery in advanced ovarian cancer”. Int. J. Gynecol. Cancer, 2010, 20, 1331.